alvimopan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	143	156053-89-3

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

alvimopan dihydrate
alvimopan anhydrous
LY246736
LY-246736
alvimopan
entereg

mu opioid receptor antagonist; intended to treat constipation in patients taking opiates for pain

Molecular weight: 424.54
Formula: C25H32N2O4
CLOGP: 2.16
LIPINSKI: 0
HAC: 6
HDO: 3
TPSA: 89.87
ALOGS: -4.71
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.10 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	2 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.81 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	6 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.43 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	5.84 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.20 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	5.30 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
May 20, 2008	FDA	CUBIST PHARMS

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anastomotic leak	53.39	51.16	7	66	624	34956234

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A06AH02	ALIMENTARY TRACT AND METABOLISM DRUGS FOR CONSTIPATION DRUGS FOR CONSTIPATION Peripheral opioid receptor antagonists
FDA MoA	N0000000154	Opioid Antagonists
MeSH PA	D005765	Gastrointestinal Agents
FDA EPC	N0000175691	Opioid Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Postoperative ileus	indication	235833007
Myocardial infarction	contraindication	22298006	DOID:5844
Hepatic failure	contraindication	59927004
Chronic renal failure syndrome	contraindication	90688005

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.38	acidic
pKa2	9.82	acidic
pKa3	9.22	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
12MG	ENTEREG	CUBIST PHARMS	N021775	May 20, 2008	DISCN	CAPSULE	ORAL	8946262	Feb. 12, 2030	A METHOD TO ACCELERATE THE TIME TO GASTROINTESTINAL RECOVERY BY ADMINISTERING ABOUT 12 MG OF ALVIMOPAN TO THE PATIENT FROM ABOUT 30 TO 60 MINUTES PRIOR TO SURGERY

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Mu-type opioid receptor	GPCR	P35372	OPRM_HUMAN	ANTAGONIST	Ki	9.40		WOMBAT-PK	CHEMBL
Kappa-type opioid receptor	GPCR	P41145	OPRK_HUMAN		Ki	7		CHEMBL
Delta-type opioid receptor	GPCR	P41143	OPRD_HUMAN		Ki	7.92		CHEMBL
Kappa-type opioid receptor	GPCR		OPRK_CAVPO		Ki	8.30		CHEMBL

External reference:

ID	Source
4025232	VUID
N0000179783	NUI
D02878	KEGG_DRUG
1516803	RXNORM
C1508750	UMLSCUI
CHEBI:135686	CHEBI
NG0	PDB_CHEM_ID
CHEMBL270190	ChEMBL_ID
DB06274	DRUGBANK_ID
C419502	MESH_SUPPLEMENTAL_RECORD_UI
5488548	PUBCHEM_CID
7471	IUPHAR_LIGAND_ID
677C126AET	UNII
136917	MMSL
25351	MMSL
341264	MMSL
d07141	MMSL
437886007	SNOMEDCT_US
437917007	SNOMEDCT_US
8245	INN_ID
4025232	VANDF
170098-38-1	SECONDARY_CAS_RN
012792	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ALVIMOPAN	HUMAN PRESCRIPTION DRUG LABEL	1	0254-3012	CAPSULE	12 mg	ORAL	ANDA	26 sections
Alvimopan	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2312	CAPSULE	12 mg	ORAL	ANDA	26 sections
Alvimopan	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2312	CAPSULE	12 mg	ORAL	ANDA	26 sections
Entereg	HUMAN PRESCRIPTION DRUG LABEL	1	67919-020	CAPSULE	12 mg	ORAL	NDA	29 sections
Entereg	HUMAN PRESCRIPTION DRUG LABEL	1	67919-020	CAPSULE	12 mg	ORAL	NDA	29 sections
Entereg	HUMAN PRESCRIPTION DRUG LABEL	1	67919-020	CAPSULE	12 mg	ORAL	NDA	29 sections